Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SPL for OTCs

This article was originally published in The Tan Sheet

Executive Summary

The Center for Drug Evaluation & Research will focus on structured product labeling (SPL) requirements for OTC drugs once it gets past the initial launch of SPL for Rx drugs in late October, CDER Office of Business Project Support Program Manager Lisa Stockbridge stated. Starting Oct. 31, manufacturers must submit label changes in electronic format using structured product labeling for all NDAs and ANDAs. Focus on SPL for OTCs is targeted for August 2006, she said during the Regulatory Affairs Professional Society annual meeting in Baltimore, Md., Oct. 17. Transition to SPL has been delayed several times since FDA's release of draft guidance on the topic in February 2004; the final guidance was issued in April. Implementing SPL places a "larger workload" on CDER, with the biggest burden on generic drugs due to a higher volume of labeling, Stockbridge said. The FDAer urged patience as the agency begins to adapt to the new system...

You may also be interested in...



Future OTC Technologies Will Bring Regulatory Challenges – Gottlieb

Technological changes in the OTC drug marketplace will prompt changes in the approval process for nonprescription products, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD

Belgium Outlaws OTC Cough And Cold Combination Drugs

Safety concerns prompt Belgium's drug regulator to order all OTC fixed combination products for coughs and colds removed from shelves.

Allegations Of EU Notified Body Fees Having Escalated And Of Being Unpredictable

US medtech companies are worried EU notified bodies have too much freedom over setting their fees, accusing them of lacking transparency and being inconsistent with what they charge. They also allege that notified body practices mean some products will miss the four-year grace period.


Topics

UsernamePublicRestriction

Register

PS098765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel